These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1698375)

  • 1. Tetracycline and 13-cis-retinoic acid inhibit production and activity of granulocyte activating factor (GAF) from Propionibacterium acnes.
    Pulverer G; Ko HL; Beuth J; Roszkowski W
    Zentralbl Bakteriol; 1990 Aug; 273(3):362-8. PubMed ID: 1698375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte activating factor released from Propionibacterium acnes. A possible mediator of inflammation in acne vulgaris.
    Pulverer G; Roszkowski W; Beuth HJ; Ko HL; Quie P
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 270(1-2):246-51. PubMed ID: 2975904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils.
    Jain A; Sangal L; Basal E; Kaushal GP; Agarwal SK
    Dermatol Online J; 2002 Oct; 8(2):2. PubMed ID: 12546757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin.
    Webster GF; Leyden JJ; McGinley KJ; McArthur WP
    Antimicrob Agents Chemother; 1982 May; 21(5):770-2. PubMed ID: 7049078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subminimal inhibitory concentrations of erythromycin, tetracycline, clindamycin, and minocycline on the neutrophil chemotactic factor production in Propionibacterium acnes biotypes 1-5.
    Akamatsu H; Nishijima S; Takahashi M; Ushijima T; Asada Y
    J Dermatol; 1991 May; 18(5):247-51. PubMed ID: 1834712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of bacterial skin flora during oral treatment of severe acne with 13-cis retinoic acid.
    Weissmann A; Wagner A; Plewig G
    Arch Dermatol Res; 1981; 270(2):179-83. PubMed ID: 6454395
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of tetracyclines and erythromycin on complement activation in vitro.
    Ingham E
    Acta Derm Venereol; 1990; 70(6):531-4. PubMed ID: 1981435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid Lipid Nanoparticles Loaded with Retinoic Acid and Lauric Acid as an Alternative for Topical Treatment of Acne Vulgaris.
    Silva EL; Carneiro G; De Araújo LA; Trindade Mde J; Yoshida MI; Oréfice RL; Farias Lde M; De Carvalho MA; Dos Santos SG; Goulart GA; Alves RJ; Ferreira LA
    J Nanosci Nanotechnol; 2015 Jan; 15(1):792-9. PubMed ID: 26328443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The resistance of Propionibacterium acnes and Staphylococcus epidermidis to cyclines. The Research and Study Group on Acne].
    Noyon V; Legallou F; Richet H; Dreno B
    Ann Dermatol Venereol; 1998 Dec; 125(12):885-7. PubMed ID: 9922860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition.
    Lee WL; Shalita AR; Suntharalingam K; Fikrig SM
    Infect Immun; 1982 Jan; 35(1):71-8. PubMed ID: 7054130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of ellagic acid and tetracycline inhibits biofilm formation and the associated virulence of Propionibacterium acnes in vitro and in vivo.
    Sivasankar C; Maruthupandiyan S; Balamurugan K; James PB; Krishnan V; Pandian SK
    Biofouling; 2016; 32(4):397-410. PubMed ID: 26930280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 13-cis-retinoic acid on sebum production and Propionibacterium acnes in severe nodulocystic acne.
    Leyden JJ; McGinley KJ
    Arch Dermatol Res; 1982; 272(3-4):331-7. PubMed ID: 6219631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetracycline and minocycline treatment.
    Leyden JJ; McGinley KJ; Kligman AM
    Arch Dermatol; 1982 Jan; 118(1):19-22. PubMed ID: 6460472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of propionibacteria to antibiotics used in the treatment of acne.
    Brown JM; Poston SM
    J Med Microbiol; 1983 Aug; 16(3):271-80. PubMed ID: 6224016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin.
    Webster GF; McGinley KJ; Leyden JJ
    Br J Dermatol; 1981 Apr; 104(4):453-7. PubMed ID: 6786318
    [No Abstract]   [Full Text] [Related]  

  • 16. In-vitro evaluation of marine derived fungi against Cutibacterium acnes.
    Agrawal S; Adholeya A; Barrow CJ; Deshmukh SK
    Anaerobe; 2018 Feb; 49():5-13. PubMed ID: 29100929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of retinaldehyde against Propionibacterium acnes.
    Pechère M; Pechère JC; Siegenthaler G; Germanier L; Saurat JH
    Dermatology; 1999; 199 Suppl 1():29-31. PubMed ID: 10473957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea.
    Song M; Seo SH; Ko HC; Oh CK; Kwon KS; Chang CL; Kim MB
    J Dermatol; 2011 Jul; 38(7):667-73. PubMed ID: 21352337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal antibiotic-resistant Propionibacterium acnes carriage in acne vulgaris patients in Turkey.
    Ergin C; Ergin S; Kaleli I; Kaçar N; Sengül M; Erdoğan BS
    J Dermatol; 2006 Dec; 33(12):899-901. PubMed ID: 17169100
    [No Abstract]   [Full Text] [Related]  

  • 20. Intradermal injection of Propionibacterium acnes: a model of inflammation relevant to acne.
    De Young LM; Young JM; Ballaron SJ; Spires DA; Puhvel SM
    J Invest Dermatol; 1984 Nov; 83(5):394-8. PubMed ID: 6238104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.